GSK Inks Pact with University of Dundee for Huntington’s Therapy

The pact signals a further push from the pharmaceutical company into the rare diseases area following previous collaborations to fight Duchenne muscular dystrophy.

Pharma giant GlaxoSmithKline has inked a pact with the University of Dundee in the UK to investigate a potential treatment for Huntington's disease, a hereditary degenerative neurological disorder, symptoms of which include memory loss, depression and anxiety.

The project will be based on the findings of the University's Susan Schweiger, who has discovered that the production of the disease-causing protein of Huntington's can be controlled through a mechanism.

Professor Schweiger's team will collaborate with GSK researchers, and the pact signals a further push from the pharmaceutical company into the rare diseases area following previous collaborations to fight Duchenne muscular dystrophy.